Madison, WI
September 25-26, 2025

8.75 CE/MOC Available

Two Days. One Mission. Transforming Precision Cancer Care.

Madison, WI
September 25-26, 2025

Celebrating 10 Years of Precision Oncology in Wisconsin

This September, Madison will host a landmark program recognizing a decade of progress in precision oncology. For the first time, Advancing Pathology Education (APE) and Advancing Precision Oncology (APO) will be presented together in Wisconsin for a two-day educational experience that honors past achievements while charting the path forward.

Program Format

Advancing Pathology Education
Where diagnostic excellence drives treatment success.

Co-chairs Dr. Juan Felix (MCW) and Dr. William Rehrauer (UW) convene a program demonstrating how today’s pathology drives tomorrow’s oncology. Sessions will explore:

Advances in biomarker testing and interpretation
AI-driven image analysis and computational tools
Molecular techniques including NGS, IHC, PCR, and liquid biopsy
Actionable insights into biomarkers such as HER2-low, C-Met, BRAF, Trop-2, FOLR1, and FGFR2b

Ideal for: Pathologists, molecular scientists, laboratory directors, translational researchers.

Advancing Precision Oncology
Celebrating 10 years of innovation in Wisconsin oncology.

Under the leadership of co-chairs Dr. Jeremy Kratz and Dr. Dustin Deming (UW), we’ll look back at ten years of advances—and look ahead to what’s next in precision oncology. Sessions will include:

Expert keynote presentations from leaders in cancer research and translational science
Advances in early detection, novel target development, and therapy innovation
Integration of molecular diagnostics into treatment planning and delivery
Reflections on the history and future of precision medicine in Wisconsin

Ideal for: Oncologists, hematologists, oncology nurses, advanced practitioners, translational scientists, and multidisciplinary cancer care teams.

Why Attend?

- Celebrate 10 years of Wisconsin leadership in precision oncology
- Two days of expert-led education spanning pathology and oncology
- FREE registration and FREE CME credits
- Practical strategies you can apply immediately in clinical practice
- Opportunities for networking and collaboration with regional and national leaders

Join us in Madison to celebrate a decade of excellence and help shape the future of precision oncology.

Agenda

Event Partners

Thursday – September 25, 2025
12:00PM	Registration & Check-in
1:00PM	Welcome and Introductions – Program Chairs Juan Felix, MD, Medical College of Wisconsin William Rehrauer, PhD, University of Wisconsin
1:10PM	Breast Cancer Biomarker Testing Julie Jorns, MD, Medical College of Wisconsin
1:50PM	MMR/MSI Testing in Colorectal Cancer: Pathology-Driven Precision Care Saryn Doucette, MD, University of Wisconsin
2:30PM	Gynecological Cancer Juan Felix, MD, Medical College of Wisconsin
3:10PM	Exhibits/Break
3:40PM	Beyond Single Mutation Paradigms:How Mutant-Wild RAS Crosstalk Shapes Response to Targeted Therapies Tommy McFall, PhD, Medical College of Wisconsin
4:10PM	Lung Cancer William Rehrauer, PhD, University of Wisconsin
4:40PM	Liquid Biopsy and Digital Pathology Juan Felix, MD, Medical College of Wisconsin
5:10PM	Networking

Learning Objectives

Interpret tumor-specific biomarkers and molecular tests—e.g., HER2-low, BRCA, PD-L1, KRAS, and methods such as NGS, IHC, PCR, liquid biopsy/ctDNA and digital pathology—to inform diagnosis and treatment selection across breast, lung, gynecologic, colorectal, and prostate cancers.
Apply precision-oncology tools—omics-based profiling (KRAS in lung), computational methods, early detection strategies, and ctDNA/MRD—to case scenarios to optimize therapy sequencing and response assessment.
Integrate hereditary cancer risk evaluation and clinical trial opportunities into multidisciplinary care and identify policy/legislative considerations in Wisconsin that impact implementation of precision medicine.

Accreditation Information | 8.75 CE/MOC

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Kneed Communications. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco Joint Accreditation Provider Number: 4008163 Professions in scope for this activity are listed below.

Physicians (ACCME) Credit Designation
Amedco LLC designates this live activity for a maximum of 8.75 AMA PRA Category 1 Credits for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists and Pharmacy Technicians (ACPE) Credit Designation
Amedco LLC designates this activity for a maximum of 8.75 knowledge-based CPE contact hours.

NOTE to Pharmacists: The only ofﬁcial Statement of Credit is the one you pull from CPE Monitor. You must request your certiﬁcate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the ﬁrst week of each month for those who claimed during the month prior.

Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 8.75 ANCC contact hours.

American Board of Pathology (ABPath) MOC
This activity is registered with the American Board of Pathology Maintenance of Certiﬁcation Program for Self-Assessment Module (SAM) for 8.75 credit hours.

You must request your certiﬁcate within 45 days of the activity to meet the deadline for submission to PARS. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Learner Notification

Acknowledgement of Financial Commercial Support
No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Kneed Communications. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation Provider Number: 4008163

Professions in scope for this activity are listed below.

Physicians
Amedco LLC designates this live activity for a maximum of 8.75 AMA PRA Category 1 CreditsTM for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists & Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 8.75 knowledge-based CPE contact hours.

UAN: JA4008163-9999-25-207-L01-P | UAN: JA4008163-9999-25-207-L01-T

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Nurses
Amedco LLC designates this activity for a maximum of 8.75 ANCC contact hours.

American Board of Pathology (ABPath) MOC
This activity is registered with the American Board of Pathology Maintenance of Certification Program for Self-Assessment Module (SAM) for 8.75 credit hours.
You must request your certificate within 45 days of the activity to meet the deadline for submission to PARS. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Objectives – After Attending This Program You Should Be Able To
1. Evaluate how advancements in computational methods, early detection technologies, and pathology-based targeting are shaping the clinical application of precision medicine across cancer types.
2. Describe the evolution of precision medicine over the past decade, including key legislative milestones, historical contributions, and current strategies for integrating genomics and molecular profiling into routine cancer care.
3. Apply knowledge of novel biomarker discovery and targeted therapy development—including hereditary cancer risk and clinical trial integration—to inform individualized treatment planning and improve patient outcomes.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

Name Commercial Interest:Relationship

Mark Burkard: NA
Jane Churpek: UpToDate, Inc:Other
Dustin Deming: Pfizer, Seagen, Eli Lilly, Foundation Medicine, Illumina, Regeneron, Aadi Biosciences, Taiho, Inocras, DoMoreDx, Fortvita, Bristol Myers Squibb, Exelixis:Scientific/Medical Advisory Board Member Merck, Genentech, Bristol Myers Squibb, Aadi Biosciences, Pfizer, Curegenix, Promega, Natera, STRATA Oncology, Cornerstone Pharmaceuticals, Arcus, Guardant Health, Ipsen, Takeda, Eli Lilly, Transthera:Research Grant Site Principal Investigator
Saryn Doucette: NA
Juan Felix: NA
Grzegorz Gurda: NA
Julie Jorns: NA
Mandana Kamgar: 1Cell.Ai:Research Grant Site Principal Investigator Cornerstone Pharmaceuticals:Research Grant Overall Principal Investigator
Paraic Kenny: Corbus Pharmaceuticals:Consultant, Tempus AI:Research Grant Site Principal Investigator
Jeremy Kratz: Boehringer Ingelheim, AstraZeneca:Consultant, BMS, Mirati:Other, Bayer, Apollomics, Roche/Genentech, Astellas, Parabilis Medicines, Johnson & Johnson:Research Grant Site Principal Investigator
Thomas McFall: NA
Muhammed Murtaza: Translational Genomics Research Institute:Consultant
Irene Ong: NA
William Rehrauer: NA
Kelda Roys: NA
Deanna Russell: NA
Nigel Russell: NA
Ravi Salgia: NA
Naomi Terlouw: NA

How to Get Your Certificate
1. Go to kc.cmecertificateonline.com
2. Click on the 2025 Advancing Precision Oncology: Celebrating 10 Years of Excellence in Wisconsin Precision
Oncology link.
3. Evaluate the meeting.
4. Print, download, or save your certificate for your records.
5. If you lose your certificate, or need help, go to help.cmecertificateonline.com

Friday – September 26, 2025
7:30 AM	Registration & Check-in
8:30 AM	Welcome Address: Precision Medicine in Wisconsin Legislation Senator Kelda Roys, JD
8:40 AM	Omics of Lung – Precision Oncology of KRAS Ravi Salgia, MD, PhD, City of Hope
9:05 AM	A Coming of Age for Precision Medicine Mark Burkard, MD, PhD, Holden Comprehensive Cancer Center
9:30 AM	Exhibits/Breakfast
10:00 AM	Non-CME Session: Expanded Liquid Testing With Genomic and Epigenomic Insights Justin Odegaard, MD, PhD, Guardant Health
10:20 AM	Break/Exhibits
10:50 AM	Applying Computational Methods in Clinical Practice Irene Ong, PhD, University of Wisconsin
11:15 AM	The Future of Early Detection Muhammed Murtaza, MBBS, PhD, University of Wisconsin
11:40 AM	Hitting the Target: Novel Target Development in Breast Cancer Paraic Kenny, PhD, Kabara Cancer Research Institute
12:05 PM	Precision Targeting from the Pathology Block Grzegorz Gurda, MD, PhD, Kabara Cancer Research Institute
12:30 PM	Exhibits/Lunch
1:00 PM	Non-CME Sponsored Session: Clinical Utility of Circulating Tumor DNA (ctDNA) testing for Decision-Making Steven Sorscher, MD, Natera
1:20 PM	Break/Exhibits
1:50 PM	Precision Oncology in Pancreatic Ductal Adenocarcinoma: Real-world experience Mandana Kamgar, MD, Medical College of Wisconsin
2:15 PM	A 10-Year Summary of Developments and Contribution Dusty Deming, MD, University of Wisconsin
2:40PM	Precision Oncology in Hereditary Cancer Rish Jane E Churpek, MD, MS, University of Wisconsin
3:05PM	Integration of Precision Medicine with Clinical Trials Jeremy Kratz, MD, University of Wisconsin
3:30PM	Networking Reception